| Expression of MAGE A1 to MAGE A10 in the Forceps Biopsy and Bronchoalveolar Lavage Specimens from Patients with the Central Lung Tumor. | Expression of MAGE A1 to MAGE A10 in the Forceps Biopsy and Bronchoalveolar Lavage Specimens from Patients with the Central Lung Tumor.
Mastutik G, Rahniayu A, Marhana IA, Amin M, Ruslan SEN, Trianto HF., Free PMC Article | 02/16/2024 |
| These data suggest that MAGE-A1 is a promising candidate marker for lung adenocarcinoma (LUAD) therapy and the MAGE-A1-specific CAR-T cell immunotherapy may be an effective strategy for the treatment of MAGE-A1-positive LUAD. | MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells.
Mao Y, Fan W, Hu H, Zhang L, Michel J, Wu Y, Wang J, Jia L, Tang X, Xu L, Chen Y, Zhu J, Feng Z, Xu L, Yin R, Tang Q., Free PMC Article | 06/27/2020 |
| MAGE-A1 was found in several lung cancer patients | Overexpression of cancer-testis antigen melanoma-associated antigen A1 in lung cancer: A novel biomarker for prognosis, and a possible target for immunotherapy.
Fanipakdel A, Seilanian Toussi M, Rezazadeh F, Mohamadian Roshan N, Javadinia SA. | 05/16/2020 |
| Tumor suppressive miR-6775-3p inhibits esophageal squamous cell carcinoma progression through forming a positive feedback loop with p53 via MAGE-A family proteins. | Tumor suppressive miR-6775-3p inhibits ESCC progression through forming a positive feedback loop with p53 via MAGE-A family proteins.
Meng L, Liu F, Ju Y, Ding P, Liu S, Chang S, Liu S, Zhang Y, Lian Y, Gu L, Zhang X, Sang M., Free PMC Article | 12/14/2019 |
| GPC3, MAGE1 and 3 were increased with advanced tumor stage, size, and nodule numbers in Hepatocellular Carcinoma | Glypican-3 and Melanoma Antigen Genes 1 and 3 as Tumor Markers for Hepatocellular Carcinoma.
El-Wahab NM, Rashed HG, El-Sherif WT, Sayed SK, Abd-Elmalek MO, Refaiy A, Fakhry H, Mokhtar AA. | 04/27/2019 |
| The expression of MAGE-A genes in peripheral blood may act as a poor prognostic marker in patients with lung cancer. | MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer.
Gu L, Sang M, Yin D, Liu F, Wu Y, Liu S, Huang W, Shan B., Free PMC Article | 12/22/2018 |
| MAGE-A expression in blood or bone marrow at tumor surgery is an independent predictor of survival in resected non-small cell lung cancer | A Threshold of Systemic MAGE-A Gene Expression Predicting Survival in Resected Non-Small Cell Lung Cancer.
Mecklenburg I, Sienel W, Schmid S, Passlick B, Kufer P. | 02/10/2018 |
| Authors revealed a novel interaction between MAGEA1 and the intracellular segment of NOTCH1 receptor (NICD1). MAGEA1 reduced NICD1's stability by promoting the ubiquitin modification of NICD1. | MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
Zhao J, Wang Y, Mu C, Xu Y, Sang J. | 10/14/2017 |
| In patients with Colon cancer, the expression of MAGE-A(1-6) gene was associated with a poor prognosis. | [Cancer-testis genes in colon cancer].
Hilal NR, Novikov DV, Novikov VV, Karaulov AV. | 09/2/2017 |
| MAGEA1 was expression in 15% of synovial sarcomas and was not associated with prognosis. | Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K, Maekawa A, Kohashi K, Ishii T, Bekki H, Otsuka H, Yamada Y, Yamamoto H, Harimaya K, Iwamoto Y, Oda Y. | 09/2/2017 |
| Data show that overall survival (OS) was significantly lower for patients expressing pan-MAGE or MAGE-A1/A3/A4 in both independent cohorts. | MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy.
Laban S, Giebel G, Klümper N, Schröck A, Doescher J, Spagnoli G, Thierauf J, Theodoraki MN, Remark R, Gnjatic S, Krupar R, Sikora AG, Litjens G, Grabe N, Kristiansen G, Bootz F, Schuler PJ, Brunner C, Brägelmann J, Hoffmann TK, Perner S., Free PMC Article | 08/19/2017 |
| These data demonstrate that MAGE-A1-, MAGE-A3-, and NY-ESO-1-specific T cells with antigen-specific cytotoxicity can be cultured from healthy donors and patient-derived cells making adoptive immunotherapy with these cytotoxic T lymphocyte feasible. | Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK, Wang Y, Sundaram K, Bai F, Lucas KG. | 07/29/2017 |
| up-regulation of MAGE-A1 dramatically promoted proliferation, migration, and invasion of human melanoma cell lines in vitro | MAGE-A1 promotes melanoma proliferation and migration through C-JUN activation.
Wang D, Wang J, Ding N, Li Y, Yang Y, Fang X, Zhao H. | 06/24/2017 |
| The overall survival of laryngeal squamous cell carcinoma patients with positive MAGE-A1, MAGE-A9, or MAGE-A11 expression was lower than the patients without MAGE-A1, MAGE-A9, or MAGE-A11 expression. | Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell carcinoma and their prognostic significance: a retrospective clinical study.
Liu S, Sang M, Xu Y, Gu L, Liu F, Shan B. | 01/14/2017 |
| MAGE-A is more highly expressed than NY-ESO-1 in a majority of human malignancies | MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases.
Kerkar SP, Wang ZF, Lasota J, Park T, Patel K, Groh E, Rosenberg SA, Miettinen MM., Free PMC Article | 12/24/2016 |
| TRIM31 directly binds to NSE4, suggesting the existence of a TRIM31-MAGEA1-NSE4 complex reminiscent of the NSE1-NSE3-NSE4 trimer. | The melanoma-associated antigen 1 (MAGEA1) protein stimulates the E3 ubiquitin-ligase activity of TRIM31 within a TRIM31-MAGEA1-NSE4 complex.
Kozakova L, Vondrova L, Stejskal K, Charalabous P, Kolesar P, Lehmann AR, Uldrijan S, Sanderson CM, Zdrahal Z, Palecek JJ., Free PMC Article | 12/19/2015 |
| Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein. | Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.
Schwarzenbach H, Eichelser C, Steinbach B, Tadewaldt J, Pantel K, Lobanenkov V, Loukinov D., Free PMC Article | 07/25/2015 |
| DNA methylation has a dominant role in the epigenetic hierarchy governing MAGEA1 expression | Epigenetic hierarchy within the MAGEA1 cancer-germline gene: promoter DNA methylation dictates local histone modifications.
Cannuyer J, Loriot A, Parvizi GK, De Smet C., Free PMC Article | 12/7/2013 |
| results show the absence and/or low expression of MAGE A1 transcripts in oral squamous cell carcinoma; presence of hypomethylation at a small level at the promoter site of MAGE A1 was detected in both oral squamous cell carcinoma and normal oral mucosa | Evaluation of MAGE A1 in oral squamous cell carcinoma.
Pereira CM, Gomes CC, De Fátima Correia Silva J, Bucciarelli Rodriguez M, Barbosa AA, Gomez RS. | 09/1/2012 |
| Report MAGEA1-A6 expression in sputum suggests presence of lung cancer cells or precancerous cells. | MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases.
Shin KC, Lee KH, Lee CH, Shin IH, Suh HS, Jeon CH., Free PMC Article | 06/2/2012 |
| High MAGE-1 is associated with differentiated advanced gastric cancer. | Clinical significance of melanoma antigen-encoding gene-1 (MAGE-1) expression and its correlation with poor prognosis in differentiated advanced gastric cancer.
Ogata K, Aihara R, Mochiki E, Ogawa A, Yanai M, Toyomasu Y, Ando H, Ohno T, Asao T, Kuwano H. | 07/23/2011 |
| MAGE1 expression mediated by demethylation of MAGE1 promoter induce progression of non-small cell lung cancer. | MAGE expressions mediated by demethylation of MAGE promoters induce progression of non-small cell lung cancer.
Yanagawa N, Tamura G, Oizumi H, Endoh M, Motoyama T. | 03/19/2011 |
| Observational study of gene-disease association. (HuGE Navigator) | Frequent MAGE mutations in human melanoma.
Caballero OL, Zhao Q, Rimoldi D, Stevenson BJ, Svobodová S, Devalle S, Röhrig UF, Pagotto A, Michielin O, Speiser D, Wolchok JD, Liu C, Pejovic T, Odunsi K, Brasseur F, Van den Eynde BJ, Old LJ, Lu X, Cebon J, Strausberg RL, Simpson AJ., Free PMC Article | 12/5/2010 |
| CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 have a role in anti-tumor immunity against gastric cancer | CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo.
He S, Wang L, Wu Y, Li D, Zhang Y., Free PMC Article | 10/23/2010 |
| Tumor-specific antigen MAGE may play a role in the occurrence and development of ovarian cancerc and can be used as one of the important indicators for early diagnosis, efficacy evaluation and prognostic determination of ovarian cancer. | Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines.
Zhang S, Zhou X, Yu H, Yu Y., Free PMC Article | 08/23/2010 |